Allergy & Immunology
Review: SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19.
17 Oct, 2021 | 21:30h | UTCRelated: Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.
Commentary from the author on Twitter (thread – click for more)
SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review @brosseau_lisa @KevinEscandonMD @AngelaKUlrich @angie_rasmussen Chad Roy @neuronerdsunite @SaskiaPopescu @mtosterholm
https://t.co/2rv0oH1OM5
Quick 🧵 1/ @CIDRAP @acinnacional pic.twitter.com/7lnNYu6eto— Kevin Escandón MD MSc (@KevinEscandonMD) October 15, 2021
Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines.
17 Oct, 2021 | 21:27h | UTCOriginal study: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine
Commentary on Twitter
Just published @NEJM
Neutralizing antibody levels and T cells response out to 8 months for Pfizer, Moderna and J&J vaccines https://t.co/ghAgk3Y4kR
Moderna highest antibody response; J&J while lower doesn't fall off and best CD8 T-cell response at 8 months pic.twitter.com/uANSzAylMF— Eric Topol (@EricTopol) October 15, 2021
Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.
15 Oct, 2021 | 02:49h | UTCHeterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv
Commentary: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News
Commentary on Twitter
So yes, mRNA vaccines are great at generating antibodies but what does that mean? Where is the efficacy data? How come JnJ gets really great efficacy at preventing symptomatic COVID and severe disease with low antibodies? T-cells? Still much to learn. https://t.co/YwKUyogAhQ
— Daniel Griffin MD PhD (@DanielGriffinMD) October 13, 2021
A primer on what we know about mixing and matching Covid vaccines.
13 Oct, 2021 | 01:44h | UTCA primer on what we know about mixing and matching Covid vaccines – STAT
Related:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.
8 Oct, 2021 | 10:29h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
As more & more countries consider adding a 3rd #COVID19 vaccine dose into their national immunisation programmes, vaccine reactogenicity will become important, especially if 3rd dose is different to first 2 doses. We need more mix-n-match booster studies 👉https://t.co/G57i9Ej7Nd
— Shamez Ladhani (@ShamezLadhani) October 7, 2021
Review: Eosinophilic Esophagitis.
6 Oct, 2021 | 09:51h | UTCEosinophilic Esophagitis: A Review – JAMA (free for a limited period)
Related:
Clinical Guidelines for the Management of Eosinophilic Esophagitis
Eosinophilic Esophagitis: Review and Update
Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.
3 Oct, 2021 | 22:49h | UTCCovid-19 vaccination: evidence of waning immunity is overstated – The BMJ
Related:
COVID vaccine effects wane over time but still prevent death and severe illness.
Perspective | What we actually know about waning immunity.
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Studies: COVID vaccine protection waning against infection but not hospitalization.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
24 Sep, 2021 | 08:55h | UTCRelated:
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (several resources on the subject)
Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.
23 Sep, 2021 | 10:16h | UTC
Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.
23 Sep, 2021 | 10:12h | UTC
Commentary on Twitter
Multisystem inflammatory syndrome has been reported in adults worldwide but may be hard to distinguish from acute biphasic #COVID19 and postacute sequelae of COVID-19. More research is needed to understand this emerging clinical entity. https://t.co/OnerzsZKVB
— JAMA Network Open (@JAMANetworkOpen) September 22, 2021
An FDA panel says only high-risk Americans and those 65+ should get covid boosters.
19 Sep, 2021 | 23:45h | UTCAn FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR
See also:
5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN
Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press
Related:
Third shot: UK to offer COVID booster jabs to over 50s.
COVID-19 vaccine efficacy does not support boosters for general population, review concludes.
COVID vaccine effects wane over time but still prevent death and severe illness.
What’s the evidence for COVID-19 booster shots?
COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.
19 Sep, 2021 | 23:40h | UTCCOVID vaccine immunity is waning — how much does that matter? – Nature
Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.
16 Sep, 2021 | 10:14h | UTCVaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine
Commentary on Twitter
Experience with 11 patients suggests that elements of VITT (severe headache, elevated d-dimer levels, and positivity for anti-PF4 antibodies) after ChAdOx1 nCoV-19 vaccination may precede VITT. #Covid19Vaccines #COVID19 #SARSCoV2 #IDTwitter https://t.co/mzBgjJIE6l pic.twitter.com/wGqb1gKFXk
— NEJM (@NEJM) September 15, 2021
An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.
16 Sep, 2021 | 10:13h | UTCProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel – New England Journal of Medicine
COVID vaccine effects wane over time but still prevent death and severe illness.
16 Sep, 2021 | 10:10h | UTCCOVID vaccine effects wane over time but still prevent death and severe illness – The Conversation
Related:
Perspective | What we actually know about waning immunity.
Another study shows Pfizer mRNA vaccine immunity is reduced over time.
Studies: COVID vaccine protection waning against infection but not hospitalization.
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
COVID-19 vaccine efficacy does not support boosters for general population, review concludes.
14 Sep, 2021 | 10:08h | UTCNews release: COVID-19 vaccine efficacy does not support boosters for general population, review concludes – The Lancet
Original article: Considerations in boosting COVID-19 vaccine immune responses – The Lancet
Commentaries:
FDA experts among group opposing US booster shot plan – Associated Press
FDA vaccine regulators argue against Covid-19 vaccine boosters in new international review – STAT
Global experts pan wider use of COVID vaccine booster dose – CIDRAP
Boosters Are ‘Not Appropriate’ – Reach Unvaccinated First – Health Policy Watch
Data Doesn’t Support Need for COVID-19 Vaccine Boosters: Experts – HealthDay
What’s the evidence for COVID-19 booster shots?
12 Sep, 2021 | 22:05h | UTCWhat’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal
India’s DNA COVID vaccine is a world first – more are coming.
10 Sep, 2021 | 05:30h | UTCIndia’s DNA COVID vaccine is a world first – more are coming – Nature
COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.
10 Sep, 2021 | 05:29h | UTCOriginal study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.
Perspective | What we actually know about waning immunity.
10 Sep, 2021 | 05:26h | UTCWhat We Actually Know About Waning Immunity – The Atlantic
[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.
9 Sep, 2021 | 09:55h | UTC
Commentary on Twitter (thread – click for more)
Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) or Moderna vax. Found dose 3 reduced those with no humoral or cellular response from 31% to 6% …1/2 https://t.co/HIjeDaFy7w Preprint #IC
— Hilda Bastian, PhD (@hildabast) September 8, 2021
Kids and COVID: why young immune systems are still on top.
7 Sep, 2021 | 21:46h | UTCKids and COVID: why young immune systems are still on top – Nature
[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
7 Sep, 2021 | 21:42h | UTC
Commentary on Twitter
A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an 81% risk reduction) https://t.co/ljir4DV1zU ("did not examine evidence for immunity against the new variants") pic.twitter.com/pT7A2KA9FV
— Eric Topol (@EricTopol) September 7, 2021
Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.
7 Sep, 2021 | 10:56h | UTCInvited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
Commentaries on Twitter
(thread – click for more)
Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.
Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS
— The Lancet (@TheLancet) September 2, 2021
(thread – click for more)
New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf— Eric Topol (@EricTopol) September 1, 2021
Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).
7 Sep, 2021 | 10:45h | UTCImmunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD